Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Elarofiban(RWJ-53308) 是一种新型且具有口服活性的 GPIIb/IIIa 拮抗剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,960 | 现货 | ||
5 mg | ¥ 6,860 | 现货 | ||
10 mg | ¥ 9,430 | 现货 | ||
25 mg | ¥ 13,800 | 现货 | ||
50 mg | ¥ 18,900 | 现货 | ||
100 mg | ¥ 25,500 | 现货 |
产品描述 | Elarofiban(RWJ-53308) is a novel and orally active GPIIb/IIIa antagonist. |
体外活性 | Elarofiban (RWJ-53308) is a novel nonpeptide glycoprotein IIb/IIIa (GPIIb/IIIa) antagonist that inhibits fibrinogen binding to GPIIb/IIIa with an IC(50) of 0.4+/-0.3 nM. RWJ-53308 inhibits thrombin-induced platelet aggregation in human gel-filtered platelets (IC(50)=60+/-12 nM) and platelet aggregation in human platelet-rich plasma (PRP) in response to collagen, arachidonic acid, ADP, and SFLLRN-NH(2) (IC(50)=60+/-10, 150+/-30, 70+/-4, and 160+/-80 nM, respectively).[4] |
体内活性 | The potency of Elarofiban (RWJ-53308) in dog and guinea pig PRP is similar to human PRP. RWJ-53308 inhibits ex vivo collagen- and ADP-induced platelet aggregation in conscious dogs for up to 4 h following 0.3 mg/kg iv, and through 4 and 6 h following 1 and 3 mg/kg po. Oral bioavailability is 16+/-7%. RWJ-53308 reduces thrombus weight in a canine arteriovenous (AV) shunt model following intravenous (0.01-0.1 mg/kg) and oral (3 mg/kg) administration. In a guinea pig carotid artery pinch-injury model, RWJ-53308 completely suppresses thrombus-induced cyclic flow reductions (CFR) at 0.7 mg/kg iv. RWJ-53308 also blocks thrombus formation in photoactivation- and ferric chloride-induced models of thrombosis in guinea pigs at 0.3 and 1 mg/kg iv, respectively. In summary, RWJ-53308 is a potent orally active GPIIb/IIIa antagonist that may be useful for both acute and chronic treatment of arterial thrombotic disorders.[4] |
别名 | RWJ-53308, RWJ 53308, RWJ53308 |
分子量 | 416.51 |
分子式 | C22H32N4O4 |
CAS No. | 198958-88-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (144.05 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4009 mL | 12.0045 mL | 24.009 mL | 60.0226 mL |
5 mM | 0.4802 mL | 2.4009 mL | 4.8018 mL | 12.0045 mL | |
10 mM | 0.2401 mL | 1.2005 mL | 2.4009 mL | 6.0023 mL | |
20 mM | 0.12 mL | 0.6002 mL | 1.2005 mL | 3.0011 mL | |
50 mM | 0.048 mL | 0.2401 mL | 0.4802 mL | 1.2005 mL | |
100 mM | 0.024 mL | 0.12 mL | 0.2401 mL | 0.6002 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Elarofiban 198958-88-2 Cytoskeletal Signaling Integrin RWJ-53308 RWJ 53308 RWJ53308 Inhibitor inhibitor inhibit